Hubbry Logo
PamabromPamabromMain
Open search
Pamabrom
Community hub
Pamabrom
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Pamabrom
Pamabrom
Pamabrom
View on Wikipedia
from Wikipedia
Pamabrom
Clinical data
AHFS/Drugs.comMultum Consumer Information
MedlinePlusa681004
ATC code
  • none
Legal status
Legal status
Identifiers
  • 1:1 mixture of 2-amino-2-methyl-1-propanol and 8-bromotheophyllinate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.009.186 Edit this at Wikidata
Chemical and physical data
Formula8-Bromotheophylline: C7H7BrN4O2
2-Amino-2-methyl-1-propanol: C4H11NO
Molar mass348.20 g/mol
3D model (JSmol)
  • Cn2c(=O)c1[nH]c(Br)nc1n(C)c2=O.NC(C)(C)CO
  • InChI=1S/C7H7BrN4O2.C4H11NO/c1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14;1-4(2,5)3-6/h1-2H3,(H,9,10);6H,3,5H2,1-2H3 checkY
  • Key:ATOTUUBRFJHZQG-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Pamabrom is a product included in retail drugs available in over-the-counter medications. The active diuretic ingredient in pamabrom is 8-bromotheophylline and it also contains aminoisobutanol.

Pamabrom is available in combination with acetaminophen (paracetamol) for various conditions such as back pain and menstrual relief.[1] The acetaminophen helps reduce menstrual pains and the pamabrom reduces associated bloating. The combination is available in a number of products from various brands under different names (Midol Teen, others). The dosages are essentially the same for each brand, including generic drug store varieties.

A diuretic is also used to reduce edema (fluid buildup) in the body. Edema can cause swelling of the extremities, such as in the hands and feet. Edema can make it harder for the heart to work properly, and it can be related to congestive heart failure.

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Pamabrom

View on Grokipedia
from Grokipedia
Pamabrom is a mild formulated as a 1:1 mixture of 2-amino-2-methyl-1-propanol and 8-bromotheophylline (a methylxanthine derivative), with the molecular formula C11H18BrN5O3 and a molecular weight of 348.20 g/mol. It is primarily used in over-the-counter medications to relieve symptoms of temporary water retention, including bloating, swelling, and feelings of fullness, particularly those associated with (PMS). Pamabrom exerts its effects by increasing production, which helps reduce buildup in the body and alleviate related discomfort. This diuretic activity stems from its methylxanthine component, which promotes mild without the stronger effects of prescription . It is commonly available in standalone products like Diurex Max or in combination formulations with analgesics such as acetaminophen and antihistamines like pyrilamine to address a broader range of PMS symptoms, including cramps, headaches, and fatigue. Typical dosing involves taking it 5–6 days before the menstrual period begins, up to four doses per day, though use should not exceed 10 days without improvement. Safety considerations for pamabrom include its classification as potentially in large amounts, though it carries no drug-induced (DILI) concern. Common side effects are minimal, with gold-colored urine being a harmless and expected occurrence; however, allergic reactions such as or swelling require immediate medical attention. It is contraindicated in individuals with allergies to its components or those unable to urinate, and consultation with a healthcare provider is advised for pregnant or individuals.

Medical Uses

Primary Indications

Pamabrom is primarily indicated as a mild for the temporary relief of bloating, swelling, feelings of fullness, and water weight gain associated with (PMS) and menstrual periods. It is available over-the-counter (OTC) and is formulated to address these symptoms by promoting increased urine output without the potency of prescription diuretics. In combination therapies, pamabrom is frequently paired with analgesics such as acetaminophen to provide broader relief from menstrual-related symptoms, including cramps, , muscle aches, headaches, and . Products like Bloat Relief and Pamprin Max contain pamabrom alongside other active ingredients to target these multifaceted discomforts during the . Similarly, Diurex Aquagels incorporate pamabrom for standalone action focused on premenstrual and menstrual . Its short-term application emphasizes relief rather than long-term management, aligning with its mild profile suitable for non-prescription use.

Dosage and Administration

Pamabrom is available over-the-counter primarily as a 50 mg oral capsule or tablet for monotherapy use in relieving temporary weight gain and associated with premenstrual symptoms. The standard adult dosage is one 50 mg capsule taken after breakfast with a full glass of , which may be repeated every six hours as needed, not exceeding four capsules (200 mg total) per day. In combination products, such as those with acetaminophen for menstrual pain relief, pamabrom is typically formulated at 25 mg per caplet or tablet alongside 325 mg or 500 mg of acetaminophen. For these formulations, the recommended adult dosage is one to two caplets every four to six hours as needed, with a maximum of eight caplets per day, though total daily acetaminophen intake must not exceed 4,000 mg to avoid liver risks. Pamabrom products are administered orally, swallowed whole with water, preferably with or after a meal to minimize stomach upset, and are intended for short-term use of up to 10 days or until symptoms subside. Users should not exceed the recommended dose or duration without consulting a healthcare provider. For adolescents aged 12 years and older, dosing mirrors adult guidelines, such as in formulations like Teen (500 mg acetaminophen/25 mg pamabrom), with one to two caplets every four to six hours, not exceeding six to eight caplets daily depending on the product strength. Lower-strength options or reduced frequency may be advised for younger teens, and use in children under 12 years requires physician consultation; all users must adhere strictly to label directions to prevent overuse.

Pharmacology

Mechanism of Action

Pamabrom is a 1:1 salt complex consisting of 8-bromotheophylline, a derivative, and 2-amino-2-methyl-1-propanol, with the 8-bromotheophylline serving as the pharmacologically active moiety. The primary involves inhibition of sodium reabsorption in the proximal renal tubules, coupled with increased permeability of the renal tubules and elevated . This process enhances the urinary excretion of sodium and chloride ions, promoting osmotic diuresis and subsequent water loss without causing substantial electrolyte disturbances. Additionally, pamabrom antagonizes receptors, which further contributes to its mild effects by modulating renal blood flow and tubular function. In the context of menstrual symptom relief, pamabrom reduces fluid retention triggered by hormonal variations during the , thereby indirectly mitigating associated and swelling. Compared to more potent agents like , pamabrom exerts a weaker action, rendering it appropriate for over-the-counter management of mild, transient water retention rather than clinical conditions requiring aggressive .

Pharmacokinetics

Pamabrom, a 1:1 salt complex of 8-bromotheophylline and 2-amino-2-methyl-1-propanol, is rapidly absorbed after , with the active component 8-bromotheophylline reaching peak plasma concentrations within approximately 1.4 hours following a single 25 mg dose in healthy adult females. In this study, the mean maximum plasma concentration (Cmax) was 3.69 μg/mL, and the time to peak (Tmax) was 1.41 hours, indicating efficient gastrointestinal uptake suitable for over-the-counter use. Limited data exist on the distribution of pamabrom. The volume of distribution for 8-bromotheophylline has not been determined, and protein binding characteristics remain uncharacterized in available pharmacokinetic studies. As a derivative, it is expected to distribute into extracellular fluids, including renal tissues, to exert its effects, though quantitative details are lacking. The metabolism of 8-bromotheophylline, the pharmacologically active moiety of pamabrom, has not been extensively studied or characterized. No specific metabolites or hepatic pathways, such as demethylation common to related , have been identified in human pharmacokinetic evaluations. Excretion of pamabrom occurs primarily via the renal route, aligning with its role as a mild that promotes urinary output. In a single-dose pharmacokinetic study, the apparent terminal elimination of 8-bromotheophylline was 21.35 hours, with biexponential decline in plasma concentrations suggesting ongoing renal clearance over an extended period. The area under the plasma concentration-time curve from zero to infinity (AUC0-∞) was 46.21 μg·h/mL, reflecting sustained exposure consistent with renal elimination. Pharmacokinetic data in patients with renal impairment are unavailable; caution is advised in cases of or renal dysfunction to avoid exacerbating fluid loss.

Chemistry and Physical Properties

Chemical Structure

Pamabrom has the molecular formula C₁₁H₁₈BrN₅O₃ and a molecular weight of 348.20 g/mol. It appears as a fine white crystalline powder and exhibits good in , with a reported solubility greater than 30 g/100 mL at 25°C. The compound's CAS number is 606-04-2. Pamabrom is an equimolar (1:1) complex of 2-amino-2-methylpropan-1-ol (molecular formula C₄H₁₁NO) and 8-bromotheophylline (molecular formula C₇H₇BrN₄O₂). The latter component is a brominated derivative, specifically 8-bromo-1,3-dimethyl-7H-purine-2,6-dione, which contributes the core structure related to . This complex forms as a salt, in which the amino group of 2-amino-2-methylpropan-1-ol acts as a base to pair ionically with the acidic 8-bromotheophylline, thereby enhancing the overall aqueous of the derivative. The IUPAC name for pamabrom reflects this combination: 2-amino-2-methylpropan-1-ol; 8-bromo-1,3-dimethyl-7H-purine-2,6-dione. A textual representation of the structure can be given via SMILES notation: CC(C)(CO)N.CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Br.

Synthesis and Preparation

Pamabrom is historically prepared through the bromination of at the 8-position using in glacial acetic acid and water, yielding 8-bromotheophylline, which is then combined with 2-amino-2-methyl-1-propanol to form the water-soluble salt and improve its pharmaceutical utility. The primary synthesis route involves the direct reaction of 8-bromotheophylline with 2-amino-2-methyl-1-propanol in equimolar ratios (typically 1:1 to 1:1.3) under neutral aqueous conditions, heated to 50–55°C with stirring for 10–20 minutes, followed by hot , addition for crystallization, and vacuum drying at 50–60°C. Refinement of the crude product is achieved by dissolution in 75–90% with decolorization at 50–55°C, hot , and recrystallization, resulting in high-purity pamabrom. On an industrial scale, pamabrom production relies on straightforward mixing and heating processes in pharmaceutical facilities, with overall yields exceeding 86% and purity standards of ≥99.0% as measured by (HPLC). (USP) specifications require pamabrom to contain 72.2–76.6% 8-bromotheophylline and 24.6–26.6% 2-amino-2-methyl-1-propanol on an basis, with water content not exceeding 3% and theophylline impurities limited to ≤0.5%. Pamabrom exhibits good stability under normal storage conditions in well-closed containers at room temperature, with minimal degradation via pathways such as neutral hydrolysis. Stress studies confirm low degradation (≤6–17%) under thermal (80°C, 5 days) and photolytic (sunlight, 12 days) conditions, though significant breakdown occurs in acidic (1 M HCl, 70°C, 4 h: 37%), alkaline (1 M NaOH, 70°C, 2 h: 25%), and oxidative (3% H₂O₂, 40°C, 30 min: 28%) environments, producing distinct degradation products resolvable by RP-HPLC.

Adverse Effects

Common Side Effects

Pamabrom, a mild , is generally well-tolerated, but users may experience several common side effects related to its pharmacological action. One frequently reported effect is gold-colored urine, which is a harmless and transient phenomenon attributed to the derivative in pamabrom and typically resolves upon discontinuation of the medication. As a , pamabrom promotes increased frequency of , which is an expected therapeutic response indicating the drug's efficacy in reducing fluid retention. This effect can sometimes lead to mild if adequate fluid intake is not maintained, though it is usually self-limiting with proper hydration. Gastrointestinal discomfort, including , stomach upset, or , has been observed in users. Similarly, may occur as part of this mild gastrointestinal reaction. Headache and are additional transient side effects, potentially linked to shifts in fluid and balance. These symptoms are typically mild and resolve without intervention.

Serious Adverse Effects

Serious adverse effects associated with pamabrom are uncommon, but they require immediate medical intervention due to their potential severity. Severe allergic reactions, including , , itching, facial swelling (), and characterized by difficult breathing or throat swelling, have been reported. These reactions can progress rapidly and may be life-threatening if not treated promptly. Prolonged or excessive use of pamabrom, a mild , can lead to imbalances such as and , particularly in vulnerable populations like the elderly, those with renal impairment, or individuals on restricted fluid intake. These imbalances may manifest as , , or cardiac irregularities, emphasizing the need for monitoring in at-risk patients. Rare cutaneous reactions include fixed drug eruptions, which present as recurrent, erythematous, edematous, and hyperpigmented lesions, often around the mouth, as documented in case reports following pamabrom exposure. Serum sickness-like reactions, involving urticarial eruptions and systemic symptoms such as fever or , have also been attributed to pamabrom. In combination products containing pamabrom with other agents like acetaminophen or pyrilamine, isolated reports of —a severe reduction in —have occurred, though causality is not solely attributable to pamabrom. Overdose risks from pamabrom primarily involve excessive , which can cause significant , , , and irregular heartbeat. Symptomatic management and supportive care, including and replacement, are recommended in such cases.

Contraindications and Interactions

Contraindications

Pamabrom is contraindicated in patients with known to pamabrom, its components such as 8-bromotheophylline (a xanthine derivative), or other , as this may lead to allergic reactions including , difficulty , or swelling. It is also contraindicated in individuals with severe renal impairment due to the risk of exacerbated dysfunction from its effects. Additionally, pamabrom should not be used in cases of or inability to urinate, as the medication's mechanism relies on urinary and could worsen retention or . Relative contraindications include pregnancy, where pamabrom is classified as FDA C due to limited data on fetal risks, and it should be avoided unless the potential benefits outweigh possible harm to the . During , pamabrom is excreted into and may cause excessive or in the , necessitating monitoring of the child's hydration and if use is deemed necessary. Other relative contraindications encompass severe or uncorrected electrolyte disorders, such as , as pamabrom's action can intensify fluid and electrolyte loss, potentially leading to serious imbalances. Pamabrom is not recommended for use in children under 12 years of age without supervision, given the lack of established and efficacy data in this population. Caution is advised for elderly patients. Furthermore, pamabrom is not intended for long-term , as it is a mild suitable only for short-term relief of and should not replace standard antihypertensive therapy.

Drug Interactions

Pamabrom, as a derivative , may interact with other xanthines such as and , potentially leading to additive effects and stimulation, which can increase the risk of and imbalances. specifically may decrease the metabolism of bromotheophylline (the active component of pamabrom), thereby elevating its serum levels and enhancing these effects. Concurrent use of pamabrom with other diuretics can amplify , resulting in excessive fluid loss, severe , and heightened risk of , necessitating careful monitoring of levels. Similarly, when combined with antihypertensives such as inhibitors (e.g., benazepril, enalapril, ), pamabrom may produce additive hypotensive and hypovolemic effects, potentially causing acute , renal insufficiency, or acute renal failure, particularly in patients with volume depletion or . , , electrolytes, and renal function should be closely monitored during such coadministration, with consideration for dose adjustments or temporary discontinuation of the diuretic. Pamabrom is frequently combined with acetaminophen in over-the-counter formulations for menstrual symptom relief, and while no direct pharmacokinetic interaction exists between the two, excessive concurrent use can lead to cumulative hepatotoxicity due to acetaminophen's liver metabolism, especially in the presence of risk factors like alcohol consumption. Avoid concomitant use of pamabrom-containing products with antihistamines like pyrilamine and monoamine oxidase inhibitors (MAOIs), as administration within 14 days of MAOI therapy may precipitate a hypertensive crisis or other serious adverse effects. Additionally, alcohol may potentiate pamabrom's CNS-depressant effects, such as dizziness, and exacerbate dehydration through enhanced diuresis, so intake should be limited.

History and Society

Development and Approval

Pamabrom was developed in the mid-20th century as a water-soluble salt of 8-bromotheophylline, formed by combining the derivative with 2-amino-2-methylpropanol to enhance its properties and . This synthesis addressed the limited of bromotheophylline, making it suitable for in therapeutic formulations. Early research focused on its potential as a mild , with over 30 similar salts evaluated for and during this period. A pivotal early clinical study published in examined the effects of pamabrom in patients with cardiac , demonstrating its ability to promote urine output without significant adverse cardiac impacts. This work, conducted by Doherty and , marked one of the first documented evaluations of pamabrom's pharmacological action in a clinical setting, laying the groundwork for its broader application beyond severe conditions like . Subsequent investigations in the and explored its utility in milder indications, such as fluid retention, though animal model studies from this era remain limited in the available literature. Key clinical evidence supporting pamabrom's role in menstrual symptom relief emerged in later reviews, including a 2004 analysis in Expert Opinion on Pharmacotherapy that evaluated its combination with acetaminophen for primary dysmenorrhea. The review highlighted pamabrom's mild diuretic action in alleviating associated bloating and swelling, positioning it as a viable over-the-counter option despite the scarcity of large-scale randomized controlled trials (RCTs), which were constrained by its established non-prescription status. This body of work underscored pamabrom's efficacy for premenstrual and menstrual fluid retention, with limited but supportive data from smaller studies confirming its targeted benefits. Regulatory milestones for pamabrom began with its inclusion in the FDA's over-the-counter (OTC) review process in the , as part of broader evaluations of menstrual drug products. The FDA classified pamabrom as safe and effective (Category I) for OTC use as a in these formulations through the Tentative Final Monograph for Orally Administered Menstrual Drug Products, proposed in 1982 and published in 1988. Meanwhile, the parent compound bromotheophylline was reclassified as an inactive ingredient in March 1980 for standalone use, though pamabrom retained active status in combination products. This evolution reflected a shift from potential prescription applications in the mid-20th century—such as for cardiac —to widespread OTC availability for menstrual relief by the 1980s and 1990s, culminating in the final monograph elements in 1993.

Commercial Availability and Brands

Pamabrom is widely available as an over-the-counter (OTC) without a prescription in the United States and for adult use, primarily for managing symptoms associated with and , with limited availability in the through imports. In these regions, it is marketed as a mild suitable for short-term relief, with product labels typically advising consultation with a healthcare provider for use beyond 10 days or in individuals under 12 years of age. Common brands featuring pamabrom include Diurex Max, which provides 50 mg per dose for standalone diuretic action, and , a combination product containing 25 mg pamabrom alongside acetaminophen (500 mg) and pyrilamine maleate (15 mg) for multifaceted menstrual relief. Generic equivalents are also prevalent, often mirroring these formulations at lower costs and available through major pharmacies and online retailers. Pamabrom products are commonly formulated as tablets, caplets, or softgels, with strengths typically ranging from 25 mg to 50 mg per unit to accommodate varying needs for and swelling management. Internationally, it holds similar OTC approval in select Asian countries like , where it is used for comparable indications, though restrictions often limit its availability or dosing for pediatric populations.

References

  1. https://pubchem.ncbi.nlm.nih.gov/compound/Pamabrom
  2. https://www.drugs.com/mtm/pamabrom.html
  3. https://my.clevelandclinic.org/health/drugs/23881-acetaminophen-pamabrom-pyrilamine-tablets
  4. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab10451e-ff87-4974-bec4-7ba19c5bbe65
  5. https://www.ncbi.nlm.nih.gov/books/NBK560834/
  6. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c1ad6073-63f6-669f-e053-2995a90aacee
  7. https://www.verywellhealth.com/pamprin-vs-midol-8611465
  8. https://www.uspharmacist.com/article/alleviating-menstrual-discomfort-pms-and-dysmenorrhea
  9. https://synapse.patsnap.com/article/what-is-pamabrom-used-for
  10. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d6492e0-1c16-6e3a-e063-6294a90a2440
  11. https://www.rxlist.com/acetaminophen_pamabrom/generic-drug.htm
  12. https://reference.medscape.com/drug/midol-teen-acetaminophen-pamabrom-999333
  13. https://www.globalrx.com/articles?article=midol-teen-formula-clinical-profile&product_id=34063
  14. https://www.goodrx.com/acetaminophen-pamabrom-pyrilamine/midol-dosage
  15. https://www.drugs.com/cdi/midol-teen-formula.html
  16. https://go.drugbank.com/drugs/DB14018
  17. https://perks.optum.com/blog/over-the-counter-diuretic
  18. https://annexpublishers.co/full-text/JBS/3101/Bioanalytical-Method-for-Pamabrom-Determined-As-8-Bromotheophylline-and-its-Application-to-a-Pharmacokinetic-Study.php
  19. https://pubchem.ncbi.nlm.nih.gov/compound/Bromotheophylline
  20. https://patents.google.com/patent/US5306507A/en
  21. https://www.smolecule.com/products/s589595
  22. https://patents.google.com/patent/CN101671334A/en
  23. https://www.drugfuture.com/pharmacopoeia/usp32/pub/data/v32270/usp32nf27s0_m60250.html
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC4090826/
  25. https://www.drugs.com/sfx/pamabrom-side-effects.html
  26. https://www.epocrates.com/online/drugs/6414/diurex-max
  27. https://pubmed.ncbi.nlm.nih.gov/1829985/
  28. https://pubmed.ncbi.nlm.nih.gov/16573265/
  29. https://www.ncbi.nlm.nih.gov/books/NBK618282/
  30. https://www.drugs.com/disease-interactions/pamabrom.html
  31. https://www.medindia.net/doctors/drug_information/pamabrom.htm
  32. https://www.drugs.com/drug-interactions/pamabrom.html
  33. https://www.drugs.com/drug-interactions/acetaminophen-pamabrom-with-perindopril-73-0-1830-0.html?professional=1
  34. https://www.rxlist.com/acetaminophen_pamabrom_pyrilamine/generic-drug.htm
  35. https://www.drugs.com/food-interactions/acetaminophen-pamabrom-pyrilamine%2Cpamprin-maximum-pain.html
  36. https://www.researchgate.net/publication/9207644_Some_new_soluble_salts_of_8-bromotheophylline
  37. https://pubmed.ncbi.nlm.nih.gov/13080166/
  38. https://pubmed.ncbi.nlm.nih.gov/15013925/
  39. https://www.fda.gov/drugs/historical-status-otc-rulemakings/rulemaking-history-otc-menstrual-drug-products
  40. https://www.mskcc.org/cancer-care/patient-education/medications/adult/pamabrom
  41. https://www.drugs.com/ingredient/pamabrom.html
  42. https://www.amazon.com/Midol-Bloat-Relief-Caplets-Pamabrom/dp/B08W3JHG19
  43. https://www.doctoroncall.com.my/medicine/en/generics/pamabrom
Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.